To address the low understanding of idiopathic hypersomnia (IH), Jazz partnered with the Hypersomnia Foundation to launch I Have IH, a disease awareness campaign aimed at increasing knowledge of IH. In a previous Our Stories article, we focused on results from the patient and supporter surveys that unveiled the difficult and prolonged diagnosis journey people with IH and their supporters often endure. In this piece, we focus on additional results from the surveys that show the debilitating effects IH has on day-to-day life.

Idiopathic hypersomnia (IH) is a debilitating neurologic sleep disorder that is not common or widely understood. To address this lack of knowledge around the condition, Jazz partnered with the Hypersomnia Foundation to launch I Have IH, an awareness campaign highlighting physician, patient and supporter perspectives to better understand the level of knowledge of IH and its real-life impact on those living with the disorder.

As a dedicated supporter of the small cell lung cancer (SCLC) community, Jazz is focused on driving awareness of the fact that there is nothing small or unimportant about SCLC. To support this goal, Jazz and collaborators from the broader healthcare community launched Nothing Small About It (NSAI), a campaign providing solutions to reduce SCLC-related disparities.

Receiving a diagnosis of any kind has implications not just for the person on the receiving end, but also for their family, friends and the people closest to them. As part of our commitment to patients and their care teams, this National Family Caregivers Month, we shine a light on this essential role and its many nuances.

During National Family Caregivers Month, we recognize and honor family caregivers who dedicate time and resources to caring for their loved ones. Jazz is committed to raising awareness of the essential role that caregivers play and the challenges they face, and to educating communities on ways to increase support for them.

Living an adventurous life at the age of 22, Caroline thought she was pursuing her dream. At the time, she was living in Korea, where she was teaching elementary school and applying for her Ph.D. after completing a bachelor’s degree in Immunology from the University of Edinburgh. She never would have suspected that what she thought was just a regular cold, maybe caught from her young students, would ultimately lead to a life-changing and potentially life-threatening diagnosis.

As a long-time leader in neuroscience, Jazz has held a longstanding commitment to provide therapies and support for patients living with serious, debilitating neurologic disorders, to help them reclaim their lives. Even though essential tremor (ET) is considered the most common movement disorder, affecting millions of people worldwide,1 there are limited treatment options for patients.

Post-traumatic stress disorder (PTSD) is a common psychiatric condition affecting approximately 10 million Americans that can result from actual or threatened traumatic events and experiences. Learn more about the prevalence of this complex psychiatric condition and Jazz’s efforts to address the significant unmet need for patients.

Dravet syndrome is a rare, severe, lifelong form of treatment-resistant epilepsy that typically begins in the first year of life.

Jazz is committed to developing critical medicines for people living with serious neurological conditions including epilepsy. At this year’s 2022 American Epilepsy Society (AES) annual meeting, we will present data from six abstracts showcasing Jazz’s commitment to providing medicines for people living with rare forms of epilepsy with few treatment options.

In recognition of National Epilepsy Awareness Month, our Chief Executive Officer, Bruce Cozadd shares Jazz’s commitment to raising awareness of epilepsy and how we’re working to generate a greater impact and address the needs of the epilepsy community.

This year’s World Heart Day is centered around the theme of ‘Cardiovascular Health for Everyone,’ which raises awareness of the prevention, treatment and management of cardiovascular disease worldwide. At Jazz, we know that people living with sleep disorders, such as narcolepsy, face risks in developing some of these comorbidities, and we are committed to exploring solutions that can help effectively manage the impacts they face, including hypertension, cardiovascular disease, obesity and diabetes.